Slide 1: Investor Overview
Exhibit 99.1 Investor Overview NASDAQ : BIOL JUNE 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation and during discussions with BIOLASE representative’s that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements its representatives make concerning BIOL
Slide 3: BIOLASE
BIOLASE y \ @BIOLASE, Inc. 20; BIOLASE.
Slide 4: Who We Are
Who We Are BIOLASE is the worldwide leader in dental lasers. With thousands of dental lasers in use worldwide, millions of patients have experienced the benefits of laser dentistry, such as less aerosols, gentler procedures and comfortable healing.
Slide 5: There is a Better Way
There is a Better Way Click to Play
Slide 6: BIOLASE at a Glance
BIOLASE at a Glance Broad Range Complete Line 43K+ Laser of Applications of Products Systems Sold Dental lasers perform a broad For general dentists In 80 countries to date range of cosmetic, restorative and specialists and surgical applications Large IP Portfolio Massive Market Growth Experienced 3
Slide 7: Full-Spectrum of Laser Systems and Consumables
Full-Spectrum of Laser Systems and Consumables — 301 Issued + 32 Pending Patents — Epic X™ Waterlase iPlus™ Surgery, fast tooth whitening and pain Best selling All-Tissue dental laser— therapy in one device 80 FDA cleared indications Ultra portable for multiple-operatory use Replaces scalpel for min
Slide 8: Section Two: The Time is Now
SECTION TWO The Time is Now BIOLASE ©BIOLASE, Inc. 2022. Do not reproduce without express consent of BIOLASE.
Slide 9: Lasers are Widely Used in Medicine
Lasers are Widely Used in Medicine With Only 7% to 8% Penetration, Laser Dentistry is the Next Growth Market for Lasers in Medicine OP H T H A M OL OG Y (LA S I K ) Minimally invasive EA R , NO S E & T H R O A T Less bleeding/trauma DE R M I T O L O G Y Faster healing PU L M I N O L O G Y GA S T R O
Slide 10: Global Leader in Dental Lasers
Global Leader in Dental Lasers Which company/product listed below do you think of when you hear the term “GLOBAL LEADER IN DENTAL LASERS”? ANSWERED: 82 SKIPPED: 0 Biolase / Waterlase™ Convergent Dental / Solea® Fotona / Lightwalker™ Light Instraments / [XXX] Millennium / PerioLase® I am not familiar
Slide 11: A Significant Growth Opportunity
A Significant Growth Opportunity 60M People in the U.S. Alone Have Gum Disease & Increased Health Risk Due to the Connection Between Oral and Systemic Health Under-diagnosed, Under- Peri- Less Frequent Treated, Under-managed Implantitis Dentist Visits 3.0 M+ Over 1/3 85% > 60% of the U.S. implants p
Slide 12: BIOLASE Opportunity: Targeted Growth Strategy to Further Penetrate U.S. Market
BIOLASE Opportunity Targeted Growth Strategy to Further Penetrate the U.S. Market DSOs (Corporate Dentistry) PEDIATRICS 1,300 DSOs (approx. 9,000 U.S. offices) ~7K Pediatric Dentists If only 10% of DSOs adopted our lasers it would If an additional 5% of Ped Dentists adopted our lasers it would = $54
Slide 13: Section Three: A New Standard of Care
SECTION THREE A New Standard of Care
Slide 14: Research Supports New Standard of Care in Perio
Research Supports New Standard of Care in Perio New Standard of Care Two recent studies support Protocols for Perio Excellence use of BIOLASE laser o The minimally invasive Waterlase o The findings of these two new REPAIR™ protocols achieve superior studies confirm that BIOLASE’s patient reported ou
Slide 15: Periodontal Disease is a Significant Health Threat
Periodontal Disease is a Significant Health Threat Laser technology has proven to be successful in destroying the harmful bacteria causing periodontitis, as well as restoring weakened and lost bone around the roots of the teeth o European Journal of Dentistry published a peer-reviewed o According to
Slide 16: Creating New Revenue Streams for GPs
Creating New Revenue Streams for GPs Minimally Invasive Perio Protocols Gingivitis / Early Periodontitis Moderate Periodontitis/Implantitis Severe Periodontitis/Implantitis HYGIENIST DENTIST PERIODONTIST o Effectively manage non-surgical o Easily manage moderate periodontitis o Manage severe, diffic
Slide 17: Waterlase Benefits Create a Better Root Canal
Waterlase Benefits Create a Better Root Canal Creating a New Standard of Care in Endodontics EDGEPRO ® Wide range of case use with open pulp chamber or apical approach. Only 30 sec. to complete— OEM Agreement Ease of Procedure 7.5min x 8 patients = Save an hour per day! with Edge Endo Laser light en
Slide 18: Waterlase Provides Increased Safety For Dentists & Their Patients
Waterlase Provides Increased Safety For Dentists & Their Patients DENTAL WATERLASE DRILL DENTISTRY Waterlase uses High risk of cross 50 8 contamination in the dental office due to ml/min. ml/min. 80% aerosol production Less water than traditional handpieces
Slide 19: Section Four: Growth Strategy
SECTION FOUR Growth Strategy
Slide 20: Executing Our Growth Strategy Focused on Education & Training
Executing Our Growth Strategy Focused on Education & Training Waterlase Exclusive Trial Increased messaging, Specialist Academies Program (WETP) for marketing, education Expand Awareness General Practitioners & training efforts are bearing fruit 35-40 4-8 planned dentist participants 81% events for
Slide 21: Increased Marketing & Sales Efforts
Increased Marketing & Sales Efforts Biggest Improvement in the Company Over the Past Couple of Years 239 476 events events + increased attendance per event JAN DEC JAN DEC Pre-Pandemic Projected 2022 2019
Slide 22: Key Influencers and Channels
Key Influencers Earned Channels Peers Less control KOLs / (Friends & DSOs Can be difficult to execute Podium Competition) High-quality reach Associations “Main Stage” Sustaining / Guidelines Payors Study Clubs (Peer-Review Critical in novel therapies / new tech adoption Studies) Staff & Patients Ins
Slide 23: BIOLASE Partnership Program (BPP)
BIOLASE Partnership Program (BPP) First 6 Months Immediate BIOLASE = In-office Training = Customer Cash in Hand Compelling No travel, no need to Revenue Reasons to See spend time away from Puts money in the the office, staff can Their Dentist customers pocket now Enables customers participate to gen
Slide 24: Section Five: Financials
BIOLASE SECTION FIVE Financials @BIOLASE, Inc. 2022. Do not reproduce without express consent of BIOLASE,
Slide 25: Financial Overview
Financial Overview Operating Results Financial Position 3 months ended March 31, 2022 As of March 31, 2022 $10.2M 25% 47% $22M $15M $5M Revenue YoY Revenue Gross Margin Cash & Cash Inventory Receivables Growth Equivalents ($3.9M) $55M 50% $13.7M $31M >2yrs Adjusted EBITDA Annual Revenue Annual Gross
Slide 26: 1Q22 Financial Results
1Q22 Financial Results (ended March 31, 2022) Net revenue grew 25% to $10.2 million: U.S. and international revenue increased 34% and 10%, respectively, as more dental practices 81% of U.S. laser sales came from were operating during the first quarter of 2022 new customers, continuing a positive tre
Slide 27: Key Takeaways
Key Takeaways Industry and Market Increased Marketing, Recent Independent Large Market Opportunity as Lasers Leading Product Line Education and Research Supporting of Dental Lasers and Training are Driving Adoption of Laser Become a New Disposables Increased Sales Dentistry Standard of Care BIOLASE
Slide 28: biolase.com ir@biolase.com
biolase.com ir@biolase.com NASDAQ : BIOL JUNE 2022